RxDoctor Payments Data

Kayla Smith, PA

Physician Assistant · Conway, SCNPI 1750939021

Payments from drug & device makers

$508in general payments, 2019–2025

Across 16 payments — averaging $31.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$191
  • W. L. Gore & Associates, Inc.$122
  • Boehringer Ingelheim$78
  • Dexcom, Inc.$37
  • Amarin Pharma, Inc.$29
  • Xeris Pharmaceuticals, Inc.$18
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$508100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$508 in reported general payments places this provider in the 55th percentile of 1,852 physician assistant providers in South Carolina.

See all physician assistant providers in South Carolina

Medicare billing

Part B allowed, 2024
$2,808
Medicare patients
30
Services billed
106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$106,892
JardianceEmpagliflozin52$56,861
RybelsusSemaglutide22$43,634
FarxigaDapagliflozin Propanediol14$18,781
JanuviaSitagliptin Phosphate15$17,253
EliquisApixaban18$13,531
JanumetSitagliptin Phos/Metformin Hcl11$9,639
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$6,134
Atorvastatin Calcium349$3,274
Amlodipine Besylate447$3,050
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl33$2,373
Albuterol Sulfate HfaAlbuterol Sulfate97$2,234
Omeprazole118$2,021
Losartan Potassium157$1,492
Lidocaine15$1,450

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$191$150,52596 claims
Boehringer IngelheimJardiance$78$56,86152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,852 physician assistant providers in South Carolina.

Other physician assistant in Conway

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →